Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 10Condylomata Acuminata 10Papillomavirus Infections 5Vulvar Neoplasms 3Vaginal Neoplasms 3Uterine Cervical Dysplasia 1Penile Neoplasms 1Neoplasms 1Cancer Survivor 1Anus Neoplasms 1

Interventions

Cisplatin 6pembrolizumab 5fludarabine 5Nivolumab 5Cyclophosphamide 5aldesleukin 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ifosfamide 4Radiotherapy 3Ipilimumab 3fludarabine phosphate 2entinostat 2cabozantinib 2avelumab 2aflibercept 2Specimen Handling 2CTLA-4 Antigen 2Adoptive Transfer 2vinflunine 1toripalimab 1rocakinogene sifuplasmid 1ripretinib 1oncogene protein E7, Human papillomavirus type 16 1niraparib 1nimotuzumab 1lenvatinib 1enfortumab vedotin 1durvalumab 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Penile Neoplasms × Vaccines, Synthetic × Clear all
NCT06465914 2024-12-12

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Active not recruiting
9,000 enrolled
GastrointestinalGenitourinary

Anus Neoplasms, Condylomata Acuminata, Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡